Edition:
United States

Therapix Biosciences Ltd (TRPX.OQ)

TRPX.OQ on NASDAQ Stock Exchange Capital Market

5.32USD
15 Dec 2017
Change (% chg)

$-0.04 (-0.75%)
Prev Close
$5.36
Open
$5.45
Day's High
$5.45
Day's Low
$5.20
Volume
3,024
Avg. Vol
6,712
52-wk High
$10.90
52-wk Low
$4.42

Latest Key Developments (Source: Significant Developments)

Therapix Biosciences Q3 loss per share $0.30
Thursday, 9 Nov 2017 08:00am EST 

Nov 9 (Reuters) - Therapix Biosciences Ltd : :Therapix Biosciences reports third quarter 2017 financial results and provides business update.Q3 loss per share $0.30.Therapix Biosciences Ltd - ‍cash totaled $10.7 Million as of September 30, 2017, compared to $11.8 million as of June 30, 2017​.  Full Article

Therapix Biosciences and Assuta Medical Center to initiate clinical trial in obstructive sleep apnea
Wednesday, 18 Oct 2017 08:30am EDT 

Oct 18 (Reuters) - Therapix Biosciences Ltd :Therapix Biosciences and Assuta Medical Center to initiate clinical trial in obstructive sleep apnea.  Full Article

THERAPIX SIGNS FORMULATION DEVELOPMENT, CLINICAL MANUFACTURING AGREEMENT WITH CATALENT FOR THX-TS01
Friday, 6 Oct 2017 08:30am EDT 

Oct 6 (Reuters) - Therapix Biosciences Ltd :THERAPIX SIGNS FORMULATION DEVELOPMENT AND CLINICAL MANUFACTURING AGREEMENT WITH CATALENT FOR THX-TS01.THERAPIX BIOSCIENCES - ‍ENTERED EXCLUSIVE AGREEMENT WITH CATALENT PHARMA SOLUTIONS FOR FORMULATION, DEVELOPMENT AND CLINICAL MANUFACTURING OF THX-TS01​.THERAPIX BIOSCIENCES - ‍CATALENT TO DEVELOP THX-TS01 IN SOFTGEL FORM IN SUPPORT OF CO'S CLINICAL DEVELOPMENT PROGRAM.  Full Article

Therapix Biosciences posts Q2 loss per share $0.54
Thursday, 10 Aug 2017 08:00am EDT 

Aug 10 (Reuters) - Therapix Biosciences Ltd :Therapix Biosciences reports second quarter 2017 financial results and provides business update.Q2 loss per share $0.54.  Full Article

Therapix Biosciences and Hannover Medical School enter into clinical trial agreement
Monday, 8 May 2017 08:30am EDT 

May 8 (Reuters) - Therapix Biosciences Ltd :Therapix Biosciences and the Hannover Medical School enter into an investigator-initiated clinical trial agreement to assess the effect of txh-ts01 in patients with tourette syndrome.Therapix Biosciences - entered into trial agreement with hannover medical school to conduct proof-of-concept phase ii clinical study with lead compound, thx-ts01.Therapix Biosciences - trial agreement to conduct proof-of-concept phase ii clinical study with thx-ts01, for patients suffering from tourette syndrome.  Full Article

Therapix Biosciences names Josh Blacher CFO
Wednesday, 3 May 2017 08:30am EDT 

May 3 (Reuters) - Therapix Biosciences Ltd ::Therapix Biosciences announces the appointment of Josh Blacher as chief financial officer.Prior to joining Therapix, Blacher served as Chief Financial Officer at Galmed Pharmaceuticals.  Full Article

Therapix signs exclusive license agreement with Yissum
Wednesday, 5 Apr 2017 08:55am EDT 

Therapix Biosciences Ltd : Therapix signs exclusive license agreement with Yissum for nasal drug delivery technology .Therapix Biosciences - under terms of deal, Yissum to give co exclusive, sub-licensable, royalty-bearing license for nasal delivery of cannabinoids technology.  Full Article

Therapix Biosciences prices offering of 2 mln ADSs at $6 per ADS
Wednesday, 22 Mar 2017 04:09am EDT 

Therapix Biosciences Ltd : Therapix Biosciences Ltd. announces pricing of U.S. Initial public offering and NASDAQ listing .priced its initial public offering in United States of 2 million ADS at a price to public of $6.00.  Full Article

Therapix Biosciences files application with FDA for an Orphan designation for Tourette's Syndrome drug
Wednesday, 15 Jun 2016 08:00am EDT 

: Therapix biosciences ltd says estimates that an initial clinical trial will begin in h2/2016 .Therapix biosciences filed an application with the fda to approve an "orphan" designation for the drug developed based on the entourage technology for treating tourette's syndrome.  Full Article

Therapix expects to have results of Tourette's drug trial by end of first quarter

TEL AVIV Israel's Therapix Biosciences said on Monday it expects by the end of March to have the results from its mid-stage trial of a cannabinoid-based drug for treating Tourette's syndrome which could be worth billions of dollars in revenues.